Month: March 2026

Gateway Deployment Strengthens Security Upgrade Initiative – Enabling More Efficient, Effective Screening Process TORONTO, March 17, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract One Gateway (“Gateway”) system has been selected by Alabama’s Morgan County Schools (“MCS”) to strengthen security processes across its facilities. The 18-school district will initially deploy Gateway across its many high school campuses: Brewer High School, Falkville High School, Priceville High School, West Morgan High School, and Danville High School. After evaluating several weapons screening systems on the market, MCS ultimately selected Xtract One’s Gateway for its ability to enable streamlined entry and operational processes. With Gateway, MCS students,...

SAN JOSE, Calif., March 17, 2026 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (NASDAQ: POET), a leader in integrated photonics solutions for artificial intelligence networks, and Lessengers, a developer of advanced optical connectivity technologies, today announced the joint development of a 1.6T 2×DR4 optical transceiver module designed for next-generation AI clusters and hyperscale data center networks. The effort combines POET’s highly integrated optical engines, built on its Optical Interposer™ platform, with Lessengers’ Direct Optical Wiring (DOW) technology, creating a scalable architecture for high-density optical interconnects required by emerging AI infrastructure. The 1.6T 2×DR4 transceiver will utilize POET’s optical engines to integrate lasers, modulators, photodiodes,...

COLUMBIA, Md., March 17, 2026 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (“Rekor” or the “Company”), a leader in developing and implementing state-of-the-art roadway intelligence systems, today announced that it will report its annual financial results for the fiscal year ended December 31, 2025, on Tuesday, March 31, 2026, after market close. On the same day, the Company will host its earnings conference call at 4:30 p.m. Eastern Time to discuss financial and operating results. CONFERENCE CALL INFORMATION‍Any person interested in participating in the call should please dial in approximately 10 minutes before the start of the call using the following information:‍ North America: Participant Dial-In: 877-407-8037 / +1 201-689-8037‍ Click here for participant International Toll-Free access...

New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine in a new Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration. Significant...

– First ZEVASKYN® commercial patient treatment completed in December – – ZEVASKYN launch momentum building in first quarter 2026 – – $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 – CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about building a steady cadence of biopsies and treatments,” said Vish Seshadri, Chief Executive Officer of Abeona. “We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond.” ZEVASKYN (prademagene zamikeracel) updatesFirst ZEVASKYN commercial patient...

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI® (tafasitamab), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one prior line of systemic therapy. Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ: INCY) in September...

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI® (tafasitamab). The approval follows a supplemental regulatory filing and review by ANVISA under Project Orbis for MINJUVI®, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). 1 The approval is supported by data from clinical studies evaluating MINJUVI® in combination with rituximab and lenalidomide (R2), which demonstrated meaningful response rates and durable disease control in patients with previously treated...

CHARLOTTE, N.C., March 17, 2026 (GLOBE NEWSWIRE) — Terrestrial Energy Inc. (NASDAQ: IMSR) will report its fourth quarter and full year 2025 earnings before the market opens on Monday, March 30th, 2026, and will hold a conference call at 8:30am ET that day. A live webcast of the conference call will be made available on the Events section of Terrestrial Energy’s investor relations website at https://ir.terrestrialenergy.com. The earnings release and presentation will also be posted to the investor relations website prior to the conference call. The live conference call may also be accessed by dialing (877) 407-0779 or (201) 389-0914. For those unable to listen to the live conference call, a replay will be available after the call through the archived webcast in the Events section of Terrestrial Energy’s investor relations website...

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis BOSTON, March 17, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter...

Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026. The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio. The...